RP
HZNP

Riverwater Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Riverwater Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,640
Closed -$211K – 215
2022
Q2 		$211K Buy
+2,640
New +$250K 0.21% 177
2022
Q1 		– Sell
-2,640
Closed -$284K – 221
2021
Q4 		$284K Buy
+2,640
New +$288K 0.25% 162

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Riverwater Partners's HZNP Position: Q3 2022 in Review

Riverwater Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 2,640 shares — an estimated $211K sold.

Riverwater Partners first reported a position in HZNP in Q4 2021 and held it in 2 quarters. The position peaked at $284K in Q4 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Riverwater Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Riverwater Partners sold 2,640 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $211K.
  • Riverwater Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 2 quarters.
  • Riverwater Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $284K in Q4 2021.
  • 530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Riverwater Partners's 13F filing for Q3 2022, filed 8 Nov 2022.